Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

British Journal of Cancer

Volumn 106, Issue 5, 2012, Pages 955-961

  Kelly, P ^a   Paulin, F ^a   Lamont, D ^b   Baker, L ^a   Clearly, S ^a   Exon, D ^a   Thompson, A ^a,c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biomarkers; disease free survival; oesophageal carcinoma; proteomics; survival

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; PLASMA PROTEIN; PREALBUMIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; SQUAMOUS CELL CARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADENOCARCINOMA; ADULT; AGED; APOLIPOPROTEIN A-I; BLOOD PROTEINS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREALBUMIN; PROTEOMICS; SERUM AMYLOID A PROTEIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84857790738     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.15     Document Type: Article

References (35)

1. Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D (2009) Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol 9: 396-404
2. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29: 645-654 (Pubitemid 30612230)
3. Cahill DJ (2001) Protein and antibody arrays and their medical applications. J Immunol Methods 250: 81-91 (Pubitemid 32209243)
4. Chechlinska M, Kowalewska M, Nowak R (2010) Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 10: 2-3
5. Colantonio DA, Chan DW (2005) The clinical application of proteomics. Clin Chim Acta 357: 151-158 (Pubitemid 40884594)
6. Dunne B, Reynolds JV, Mulligan E, Kelly A, Griffin M (2001) A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol 54: 841-845 (Pubitemid 33063489)
7. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R (2006) Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 78: 236-244
8. Gilbert FJ, Park KGM, Thompson AM (2002) Scottish Audit of Gastric and Oesophageal Cancer. Report 1997-2000. Scottish Audit of Gastric and Oesophageal Cancer Steering Group: Edinburgh http://www.crag.scot.nhs. uk/committees/ceps/ reports/0-prelims.pdf
9. Hayashida Y, Honda K, Osaka Y, Hara T, Umaki T, Tsuchida A, Aoki T, Hirohashi S, Yamada T (2005) Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res 11: 8042-8047 (Pubitemid 41698746)
10. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347: 1662-1669 (Pubitemid 35340784)
11. Juan HF, Chen JH, Hsu WT, Huang SC, Chen ST, Yi-Chung Lin J, Chang YW, Chiang CY, Wen LL, Chan DC, Liu YC, Chen YJ (2004) Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 4: 2766-2775
12. Kelly P, Appleyard V, Murray K, Paulin F, Lamont D, Baker L, Suttie S, Exon D, Thompson A (2010) Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer 103: 232-238
13. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25: 3719-3725 (Pubitemid 47372613)
14. Kerr DJ, Midgley R (2010) Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol 28: 3210-3212
15. Kwee RM (2010) Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 254: 707-717
16. Lagergren J (2005) Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 54(Suppl 1): i1-i5 (Pubitemid 40293002)
17. Liu P, Hwang JT (2007) Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. Bioinformatics 23: 739-746 (Pubitemid 46554726)
18. Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66: 9-26
19. Malmendier CL, Lontie JF, Sculier JP, Dubois DY (1988) Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis 73: 173-180
20. Maltaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic oesophageal cancer. Cochrane Database Syst Rev 2003 CD001556
21. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier J-M, Bonvalot MD, Gignoux M (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73: 2680-2686 (Pubitemid 24166250)
22. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ (2008) SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 54: 53-60 (Pubitemid 351182596)
23. MRC (Oesophageal Working Party) 2002 Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733
24. Munro AJ (2004) Oesophageal cancer: a view over overviews. Lancet 364: 566-568 (Pubitemid 39094161)
25. Ota Y, Takagi Y, Osaka Y, Shinohara M, Hoshino S, Tsuchida A, Aoki T, Honda K, Yamada T (2007) Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer. Oncol Rep 18: 653-657
26. Park KG (2002) Gastro-oesophageal cancer: facts, myths and surgical folk lore. J R Coll Surg Edinb 47: 716-730 (Pubitemid 36097627)
27. Plebani M (2005) Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 357: 113-122 (Pubitemid 40894636)
28. Raynes JG, Eagling S, McAdam KP (1991) Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 83: 488-491
29. Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6: 149-163
30. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152: 726-732
31. Smith L, Lind MJ, Welham KJ, Cawkwell L (2006) Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer 107: 232-241 (Pubitemid 44036551)
32. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA (2005) Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241: 810-817; discussion 817-820
33. Thompson AM, Rapson T, Gilbert FJ, Park KG (2007) Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal or gastric cancer. Br J Surg 94: 578-584 (Pubitemid 46732241)
34. Vashist YK, Loos J, Dedow J, Tachezy M, Uzunoglu G, Kutup A, Yekebas EF, Izbicki JR (2011) Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol 18: 1130-1138
35. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BL, Plukker JT, van Lanschot JJ, Sloof GW (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 236: 841-851 (Pubitemid 41170846)